Kesmalea Therapeutics

Kesmalea Therapeutics is a private, preclinical-stage biotech leveraging its innovative SELFTAC® platform to create a new class of oral, CNS-penetrant protein degraders. The company aims to solve the 'size problem' associated with traditional bifunctional degraders by designing small molecules that self-assemble into active degraders in situ. Backed by a £25 million Series A round co-led by Syncona and Oxford Science Enterprise, Kesmalea is building a pipeline in oncology and CNS with a seasoned leadership team. The company's approach could significantly expand the clinical applicability of targeted protein degradation.

SELFTAC® platform: a technology that transforms large bifunctional protein degraders into small molecules with a reversible linker, enabling them to self-assemble into the active degrader in vivo. Aims to improve oral bioavailability and CNS penetration compared to traditional degraders.

Kesmalea competes in the crowded targeted protein degradation field against leaders like Arvinas, Nurix Therapeutics, and Kymera Therapeutics, who are advancing their own oral PROTACs and molecular glues. Its key differentiator is the SELFTAC platform's specific approach to solving the molecular size problem, but it must demonstrate superior drug-like properties to gain traction.